Improvement in anxiety symptoms (medium term: 12 months) · depression in adults with non‐communicable diseases
2 findings from 1 review
Treatment efficacy for depression (medium term: 12 months) · depression in adults with non‐communicable diseases
Behavioural activation probably leads to higher treatment efficacy for depression (medium term: 12 months) compared with any comparator (moderate certainty).
1 finding from 1 review
Treatment efficacy for depression (long term: 24 months) · depression in adults with non‐communicable diseases
Behavioural activation showed no clear difference in treatment efficacy for depression (long term: 24 months) compared with any comparator (moderate certainty).
1 finding from 1 review
Acceptability · depression in adults with non‐communicable diseases
Behavioural activation showed no clear difference in treatment acceptability (short term: 2 months) compared with any comparator (low certainty).
2 findings from 1 review
Improvement in depression symptoms (short term: 5–6 months) · depression in adults with non‐communicable diseases
1 finding from 1 review
Improvement in depression symptoms (medium term: 12 months) · depression in adults with non‐communicable diseases
1 finding from 1 review
Improvement in depression symptoms (long term: 5 months) · depression in adults with non‐communicable diseases
1 finding from 1 review
Quality of life (short term: 6 months) · depression in adults with non‐communicable diseases
1 finding from 1 review
Dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in scores indicating clinical improvement) at 1‐month (with actual · people with meibomian gland dysfunction
It is very uncertain whether IPL (with/without MGX) changes dry eye symptoms, measured using the SPEED score at 3 months of compared with sham or no treatment (with/without MGX) (very low certainty).
1 finding from 1 review
MD 0
Studies not reported
Very low
Incidence of adverse events at 3 months of · people with meibomian gland dysfunction
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Clinical signs—TBUT at 1 month (seconds) · people with meibomian gland dysfunction
IPL (with/without MGX) showed no clear difference in sodium fluorescein TBUT, measured in seconds, at 3 months of compared with sham or no treatment (with/without MGX) (low certainty).
1 finding from 1 review
MD 2.02
Studies not reported
Low
NIBUT, measured in seconds, at 3 months of · people with meibomian gland dysfunction
It is very uncertain whether IPL (with/without MGX) changes NIBUT, measured in seconds, at 3 months of compared with sham or no treatment (with/without MGX) (very low certainty).
1 finding from 1 review
MD 5.5
Studies not reported
Very low
Tear osmolarity, measured in mOsmol/L, at 3 months of · people with meibomian gland dysfunction
IPL (with/without MGX) showed no clear difference in tear osmolarity, measured in mOsmol/L, at 3 months of compared with sham or no treatment (with/without MGX) (low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Meibomian gland orifice plugging, at 3 months of · people with meibomian gland dysfunction
It is very uncertain whether IPL (with/without MGX) changes meibomian gland orifice plugging, at 3 months of compared with sham or no treatment (with/without MGX) (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Corneal sodium fluorescein staining, measured using a validated clinical scale, at 3 months of · people with meibomian gland dysfunction
It is very uncertain whether IPL (with/without MGX) changes corneal sodium fluorescein staining, measured using a validated… compared with sham or no treatment (with/without MGX) (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Total mortality Mean duration of 3.8 years · adults 60 years or older with primary hypertension
Antihypertensive drug leads to lower total mortality Mean duration of 3.8 years compared with placebo or no treatment (high certainty).
1 finding from 1 review
Cardiovascular mortality and morbidity Mean duration of 3.7 years · adults 60 years or older with primary hypertension
Antihypertensive drug probably leads to lower cardiovascular mortality and morbidity Mean duration of 3.7 years compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Cerebrovascular mortality + morbidity · adults 60 years or older with primary hypertension
Antihypertensive drug probably leads to lower cerebrovascular mortality and morbidity Mean duration of 3.7 years compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Coronary heart disease mortality + morbidity · adults 60 years or older with primary hypertension
Antihypertensive drug probably leads to lower coronary heart disease mortality and morbidity Mean duration of 2.9… compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults 60 years or older with primary hypertension
Antihypertensive drug may leads to higher withdrawals due to adverse effects Mean duration of 4.6 years compared with placebo or no treatment (low certainty).
1 finding from 1 review